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Is the Message Out or Just Being Ignored?*Todd D. Miller, MD,y Lawrence M. Phillips, MDzR adiation exposure from medical imaging hasbeen receiving increased scrutiny in boththe published medical data (1,2) and the lay
press (3). To address this concern with the use of car-
diac radionuclide imaging, the American Society of
Nuclear Cardiology (ASNC) published a position state-
ment in 2010 recommending that nuclear myocardial
perfusion imaging (MPI) adhere to the principle of
ALARA (“as low as reasonably achievable”) and that
by 2014, 50% of MPI studies should be performed
with a radiation exposure of #9 mSv (4). A more
recent publication from the ASNC recommends
customizing the imaging protocol to the individual
patient’s characteristics to reduce radiation expo-
sure (5). Despite these goals to reduce radiation expo-
sure, there is little published data examining patient
radiation exposure associated with imaging per-
formed in nuclear cardiology laboratories (6).SEE PAGE 1170In this issue of iJACC, Jerome et al. (7) report the
results of estimated radiation exposure from a
nationwide sample of 5,216 MPI cases performed in
1,074 nuclear imaging laboratories submitted to the
Intersocietal Accreditation Commission. This survey
data provides several interesting ﬁndings. The mean
effective dose was 14.9  5.8 mSv, with a range of
1.4 to 42.4 mSv. Only 1.1% of cases met the ASNC goal
of #9 mSv. Conversely, radiation exposure exceeded
20 mSv in almost 10% of cases. The large majority
(82.9%) of cases used a 1-day technetium99m protocol.
In these cases, the mean effective dose was 12.9 mSv,
2 mSv lower than the mean effective dose in the
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the contents of this paper to disclose.only 9.1% of cases. As anticipated, the mean effective
dose for thallium201-only studies was higher than
technetium99m cases, at 23.9 mSv. The mean effective
dose was the highest for dual (thallium201/techne-
tium99m) isotope studies at 32.8 mSv.
This study by Jerome et al. (7) represents a novel
and important contribution to the published data.
This report is the ﬁrst systematic description of ra-
diation exposure associated with cardiac MPI. The
authors were able to take advantage of the Interso-
cietal Accreditation Commission database and cap-
ture use from all regions of the country and from
multiple types of medical practices.
What do these data teach us? Studies addressing
radiation exposure need to be interpreted cautiously,
given the scientiﬁc uncertainty associated with this
topic. At face value, the results of this study might
suggest that the medical community is doing a poor
job of addressing this issue, because only 1% of the
studies performed met the ASNC threshold
of #9 mSv. A potential implication of this observation
is that a large number of patients might be placed at
increased risk of developing complications related to
radiation exposure, with malignancy representing the
greatest concern. However, there are several impor-
tant issues that should be considered when inter-
preting the results of this study. First, the 9-mSv
threshold is an arbitrarily derived value. There is no
direct data that determines when cancer risk might
increase for radiation exposure associated with
medical imaging. It is possible that there is no dif-
ference in cancer risk between exposure of the ASNC
threshold of 9 mSv and the mean effective dose in
this study of approximately 15 mSv. Second, the mean
effective dose in the majority of the population who
underwent 1-day technetium99m scans was approxi-
mately 13 mSv, closer to the 9 mSv threshold and a
fairly modest difference when interpreted in the
context of average annual background radiation
exposure for the general U.S. population of 3 mSv.
The greatest discordance was in the 10% of cases
where exposure was >20 mSv.
Miller and Phillips J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 8 , N O . 1 0 , 2 0 1 5
Editorial Comment O C T O B E R 2 0 1 5 : 1 1 7 7 – 9
1178Evaluating the potential cancer risk associated
with radiation exposure is a complex issue. Radiation
exposure should be interpreted not in isolation, but
instead in the clinical context of the patient in whom
the imaging study is performed. Factors such as pa-
tient age, weight, and other medical testing play a
role in cumulative exposure. A limitation of the study
by Jerome et al. (7) is that important clinical data were
missing, especially the appropriateness of the study,
age of the patient, body habitus, and prior radiation
exposure. Patients who are undergoing MPI for an
appropriate indication are at higher cardiac risk. The
value of the knowledge gained from the MPI scan for
correct management of the patient likely far out-
weighs the small theoretical radiation-associated
cancer risk. Radiation exposure is of greater concern
in younger than older patients, given that the esti-
mated latency period between exposure and appear-
ance of cancer is at least 10 to 20 years (4). As an
example, an 80-year-old patient who is undergoing a
single MPI scan is less likely to see a clinically rele-
vant increase in malignancy risk from the test’s ra-
diation exposure compared with a 40-year-old
patient. Image quality is directly related to the
amount of radioisotope administered. The most
common issue adversely affecting image quality is
soft tissue attenuation in obese patients. It is gener-
ally preferable to administer a higher dose of radio-
isotope and obtain images of good quality than to
administer a lower dose with suboptimal images.
Image quality can be enhanced by performing a 2-day
versus 1-day MPI study, albeit with higher radiation
exposure. It would be interesting to know the average
body mass index, in particular for the 7.5% of patients
who underwent 2-day MPI in this study. Because
cancer risk associated with radiation exposure is
likely cumulative, it would be helpful to know infor-
mation on prior MPI studies as well as other imaging
procedures associated with radiation in these pa-
tients. This information was not provided in the
current study but should be included in future
studies that address this topic.
Although considerable uncertainty exists con-
cerning radiation exposure and cancer risk, mea-
sures to limit radiation exposure are reasonable and
prudent and are recommended by several national
organizations (1,2). The study by Jerome et al. (7)
provides a useful starting point for addressing this
objective. The mean effective dose in the 1.6% of the
population who underwent thallium201-only MPI was
23.9 mSv, and it was especially high, at 32.8 mSv, in
the 7.5% of the population who underwent dualisotope imaging. Discouraging the routine use of this
radioisotope should be strongly encouraged, espe-
cially when used in a dual isotope algorithm.
Another approach to reduce radiation exposure is to
perform a stress only protocol. In this study, that
modality was utilized in only 1.4% of the population.
Wider application of this protocol should be feasible,
especially in light of recent reports of normal image
rates of 80% to 90% in patients without an estab-
lished history of coronary artery disease (8,9). The
use of ultrafast single-photon emission computed
tomography (SPECT) and positron emission tomog-
raphy (PET) imaging methodologies are associated
with lower radiation administration. Ultrafast SPECT
camera technology provides greater ﬂexibility for
choosing between radioisotope dosage and imaging
time. PET imaging is associated with lower radiation
exposure due to the short half-lives of the PET
perfusion isotopes (rubidium82 and ammoni13).
Average exposures of 2 to 3 mSv are readily
achievable with these approaches. The lowest radi-
ation exposures in this study were noted with the
newer ultrafast camera technology. Implementing
these approaches can be logistically challenging and
more expensive for individual cardiac imaging lab-
oratories. The authors’ call for performance stan-
dards and possibly ﬁnancial incentives should lead
to greater implementation of these measures.
Finally, the performance of MPI and all noninvasive
cardiac imaging should be carefully scrutinized ac-
cording to appropriate use criteria documents (10,11)
and national guidelines (12). In particular, younger
patients, who have a higher cancer risk from radia-
tion exposure, are more likely to be capable of
adequate exercise and have a normal electrocardio-
gram. Most of these individuals can be satisfactorily
assessed with a standard treadmill test without
imaging.
We believe that the message is out to clinicians
that radiation exposure in medical imaging must be
decreased. The paper by Jerome et al. (7) indicates
that current practice patterns need to be altered to
successfully translate this message into practice.
Continued education programs, technological ad-
vancements, and regulatory changes will all play a
role in attaining lower radiation exposure associated
with cardiac imaging.
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